Blood Glucose Testing Market by Product (Glucose Meter, Lancets, Test Strips), Distribution Channel (Offline, Online), End-User, Application - Global Forecast 2023-2030
The Blood Glucose Testing Market is projected to reach USD 36.92 billion by 2030 from USD 17.70 billion in 2022, at a CAGR of 9.62% during the forecast period.
Market Segmentation & Coverage:
This research report analyzes various sub-markets, forecasts revenues, and examines emerging trends in each category to provide a comprehensive outlook on the Blood Glucose Testing Market.
- Based on Product, market is studied across Glucose Meter, Lancets, and Test Strips. The Glucose Meter is further studied across Continuous Glucose Monitoring and Discrete Glucose Monitoring. The Glucose Meter commanded largest market share of 52.00% in 2022, followed by Lancets.
- Based on Distribution Channel, market is studied across Offline and Online. The Offline commanded largest market share of 91.79% in 2022, followed by Online.
- Based on End-User, market is studied across Home Care and Hospital & Clinics. The Hospital & Clinics commanded largest market share of 62.25% in 2022, followed by Home Care.
- Based on Application, market is studied across Gestational Diabetes, Type 1 Diabetes, and Type 2 Diabetes. The Type 2 Diabetes commanded largest market share of 56.23% in 2022, followed by Type 1 Diabetes.
- Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Europe, Middle East & Africa commanded largest market share of 38.48% in 2022, followed by Americas.
The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix is an indispensable tool for assessing the Blood Glucose Testing Market. It comprehensively evaluates vendors, analyzing key metrics related to Business Strategy and Product Satisfaction. This enables users to make informed decisions tailored to their specific needs. Through advanced analysis, vendors are categorized into four distinct quadrants, each representing a different level of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V). Be assured that this insightful framework empowers decision-makers to navigate the market with confidence.
Market Share Analysis:
The Market Share Analysis offers invaluable insights into the vendor landscape Blood Glucose Testing Market. By evaluating their impact on overall revenue, customer base, and other key metrics, we provide companies with a comprehensive understanding of their performance and the competitive environment they confront. This analysis also uncovers the level of competition in terms of market share acquisition, fragmentation, dominance, and industry consolidation during the study period.
Key Company Profiles:
The report delves into recent significant developments in the Blood Glucose Testing Market, highlighting leading vendors and their innovative profiles. These include A. Menarini Diagnostics s.r.l., Abbott Laboratories, ACON Laboratories, Inc., AgaMatrix, Inc., ARKRAY, Inc., B. Braun Melsungen AG, Bionime Corporation, DexCom, Inc., DiaMonTech AG, F. Hoffmann-La Roche AG, GlySens Incorporated, Indigo Diabetes NV, Johnson & Johnson Services, Inc., LifeScan, Inc., Medisana GmbH, Medtronic PLC, Merck KGaA, Nipro Corporation, Nova Biomedical Corporation, Novo Nordisk A/S, Omnipod by Insulet Corporation, OrSense Ltd., PHC Holdings Corporation, Prodigy Diabetes Care, LLC, Rossmax International Ltd., Senseonics Holdings, Inc., Sinocare Inc., Terumo Corporation, Trividia Health, Inc., and Ypsomed AG.
The report offers valuable insights on the following aspects:
- Market Penetration: It provides comprehensive information about key players' market dynamics and offerings.
- Market Development: In-depth analysis of emerging markets and penetration across mature market segments, highlighting lucrative opportunities.
- Market Diversification: Detailed information about new product launches, untapped geographies, recent developments, and investments.
- Competitive Assessment & Intelligence: Exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of leading players.
- Product Development & Innovation: Intelligent insights on future technologies, R&D activities, and breakthrough product developments.
- What is the market size and forecast for the Blood Glucose Testing Market?
- Which products, segments, applications, and areas hold the highest investment potential in the Blood Glucose Testing Market?
- What is the competitive strategic window for identifying opportunities in the Blood Glucose Testing Market?
- What are the latest technology trends and regulatory frameworks in the Blood Glucose Testing Market?
- What is the market share of the leading vendors in the Blood Glucose Testing Market?
- Which modes and strategic moves are suitable for entering the Blood Glucose Testing Market?
Note: PDF & Excel + Online Access - 1 Year
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency & Pricing
- 1.5. Language
- 1.6. Limitations
- 1.7. Assumptions
- 1.8. Stakeholders
- 2. Research Methodology
- 2.1. Define: Research Objective
- 2.2. Determine: Research Design
- 2.3. Prepare: Research Instrument
- 2.4. Collect: Data Source
- 2.5. Analyze: Data Interpretation
- 2.6. Formulate: Data Verification
- 2.7. Publish: Research Report
- 2.8. Repeat: Report Update
- 3. Executive Summary
- 4. Market Overview
- 4.1. Introduction
- 4.2. Blood Glucose Testing Market, by Region
- 5. Market Insights
- 5.1. Market Dynamics
- 5.1.1. Drivers
- 5.1.1.1. Increasing consumer prevalence of diabetics across the world
- 5.1.1.2. Benefits associated with continuous blood glucose testing over Point-of-Care glucometers
- 5.1.1.3. Rising adoption of non-invasive blood glucose testing devices in home healthcare settings
- 5.1.2. Restraints
- 5.1.2.1. High costs and limited accuracy of blood glucose testing devices
- 5.1.3. Opportunities
- 5.1.3.1. Introduction of favorable government reimbursement options for glucose meters
- 5.1.3.2. Ongoing advancements and improvements in blood glucose devices
- 5.1.4. Challenges
- 5.1.4.1. Product recalls associated with blood glucose testing products
- 5.2. Market Segmentation Analysis
- 5.3. Market Trend Analysis
- 5.4. Cumulative Impact of COVID-19
- 5.5. Cumulative Impact of Russia-Ukraine Conflict
- 5.6. Cumulative Impact of High Inflation
- 5.7. Porter’s Five Forces Analysis
- 5.7.1. Threat of New Entrants
- 5.7.2. Threat of Substitutes
- 5.7.3. Bargaining Power of Customers
- 5.7.4. Bargaining Power of Suppliers
- 5.7.5. Industry Rivalry
- 5.8. Value Chain & Critical Path Analysis
- 5.9. Regulatory Framework
- 5.10. Client Customization
- 5.10.1. Pricing Analysis & Trends
- 6. Blood Glucose Testing Market, by Product
- 6.1. Introduction
- 6.2. Glucose Meter
- 6.3.1. Continuous Glucose Monitoring
- 6.3.2. Discrete Glucose Monitoring
- 6.3. Lancets
- 6.4. Test Strips
- 7. Blood Glucose Testing Market, by Distribution Channel
- 7.1. Introduction
- 7.2. Offline
- 7.3. Online
- 8. Blood Glucose Testing Market, by End-User
- 8.1. Introduction
- 8.2. Home Care
- 8.3. Hospital & Clinics
- 9. Blood Glucose Testing Market, by Application
- 9.1. Introduction
- 9.2. Gestational Diabetes
- 9.3. Type 1 Diabetes
- 9.4. Type 2 Diabetes
- 10. Americas Blood Glucose Testing Market
- 10.1. Introduction
- 10.2. Argentina
- 10.3. Brazil
- 10.4. Canada
- 10.5. Mexico
- 10.6. United States
- 11. Asia-Pacific Blood Glucose Testing Market
- 11.1. Introduction
- 11.2. Australia
- 11.3. China
- 11.4. India
- 11.5. Indonesia
- 11.6. Japan
- 11.7. Malaysia
- 11.8. Philippines
- 11.9. Singapore
- 11.10. South Korea
- 11.11. Taiwan
- 11.12. Thailand
- 11.13. Vietnam
- 12. Europe, Middle East & Africa Blood Glucose Testing Market
- 12.1. Introduction
- 12.2. Denmark
- 12.3. Egypt
- 12.4. Finland
- 12.5. France
- 12.6. Germany
- 12.7. Israel
- 12.8. Italy
- 12.9. Netherlands
- 12.10. Nigeria
- 12.11. Norway
- 12.12. Poland
- 12.13. Qatar
- 12.14. Russia
- 12.15. Saudi Arabia
- 12.16. South Africa
- 12.17. Spain
- 12.18. Sweden
- 12.19. Switzerland
- 12.20. Turkey
- 12.21. United Arab Emirates
- 12.22. United Kingdom
- 13. Competitive Landscape
- 13.1. FPNV Positioning Matrix
- 13.2. Market Share Analysis, By Key Player
- 13.3. Competitive Scenario Analysis, By Key Player
- 13.3.1. Merger & Acquisition
- 13.3.1.1. Etao International Group Announces Acquisition of Dnurse, a Provider of Personalized, Integrated, and Technology-Empowered Diabetes Management Solutions
- 13.3.1.2. Lilly Announces Acquisition of Protomer Technologies
- 13.3.2. Agreement, Collaboration, & Partnership
- 13.3.2.1. Terumo and Glooko Announce Collaboration on New Solution for Diabetes Data Sharing
- 13.3.2.2. 9am.health and Ascensia partner on diabetes toolkit blood glucose meter
- 13.3.3. New Product Launch & Enhancement
- 13.3.3.1. DexCom to launch new glucose monitoring system
- 13.3.3.2. Intuity Medical launches POGO glucose monitoring system
- 13.3.4. Investment & Funding
- 13.3.4.1. Glucose monitor health startup snags $4M in seed funding
- 13.3.4.2. DiaMonTech attracts $5 million from Samsung Ventures and U.S.-based venture capitalists to bring its new non-invasive glucose monitor to the U.S.
- 13.3.5. Award, Recognition, & Expansion
- 13.3.5.1. Abbott's FreeStyle Libre is First and Only CGM System to Gain Expanded Reimbursement in Japan to Include All People with Diabetes Who Use Insulin
- 13.3.5.2. Senseonics' long-lasting continuous glucose monitor receives FDA approval
- 14. Competitive Portfolio
- 14.1. Key Company Profiles
- 14.1.1. A. Menarini Diagnostics s.r.l.
- 14.1.2. Abbott Laboratories
- 14.1.3. ACON Laboratories, Inc.
- 14.1.4. AgaMatrix, Inc.
- 14.1.5. ARKRAY, Inc.
- 14.1.6. B. Braun Melsungen AG
- 14.1.7. Bionime Corporation
- 14.1.8. DexCom, Inc.
- 14.1.9. DiaMonTech AG
- 14.1.10. F. Hoffmann-La Roche AG
- 14.1.11. GlySens Incorporated
- 14.1.12. Indigo Diabetes NV
- 14.1.13. Johnson & Johnson Services, Inc.
- 14.1.14. LifeScan, Inc.
- 14.1.15. Medisana GmbH
- 14.1.16. Medtronic PLC
- 14.1.17. Merck KGaA
- 14.1.18. Nipro Corporation
- 14.1.19. Nova Biomedical Corporation
- 14.1.20. Novo Nordisk A/S
- 14.1.21. Omnipod by Insulet Corporation
- 14.1.22. OrSense Ltd.
- 14.1.23. PHC Holdings Corporation
- 14.1.24. Prodigy Diabetes Care, LLC
- 14.1.25. Rossmax International Ltd.
- 14.1.26. Senseonics Holdings, Inc.
- 14.1.27. Sinocare Inc.
- 14.1.28. Terumo Corporation
- 14.1.29. Trividia Health, Inc.
- 14.1.30. Ypsomed AG
- 14.2. Key Product Portfolio
- 15. Appendix
- 15.1. Discussion Guide
- 15.2. License & Pricing
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook